Your fact-checks will appear here
Danish pharmaceutical company
President Trump publicly claimed extraordinarily large drug-price reductions — citing figures like “500%, 600%, 1,000%, 1,500%” — during July and August 2025 remarks and in subsequent events; fact‑che...
The Trump administration and its allies pursued a mix of executive actions, private-sector deals and agency directives that lowered some insulin costs for specific groups while leaving statutory caps ...
The are a fast‑growing mass‑tort movement alleging that widely prescribed glucagon‑like peptide‑1 receptor agonists — including , and — caused serious harms such as , intestinal blockages and vision l...
There is no credible reporting in the provided sources that President Trump “took $100 million from pharma” as a personal payment. The record in these documents shows aggressive White House pressure o...
has publicly linked his weight loss to —variously naming Wegovy, Ozempic and most recently ’s Mounjaro—remarks that have amplified public interest and market demand for these drugs . Reporting shows M...
Available reporting does not show Donald Trump personally investing his own money into pharmaceutical companies; instead, the Trump administration in 2025 pushed a set of deals and threatened tariffs ...
The Trump administration and White House fact sheets have frequently presented drug-price “reductions” as large percentage drops — including claims as high as “500%–1,500%” — but those numbers are mat...
BurnPeak is marketed as a dietary supplement built on BHB ketone salts and plant extracts and claims appetite control and “natural fat-burning,” but available sources provide only marketing-style, unv...
President Trump’s recent healthcare maneuvering centers on extending ACA premium subsidies for two years while proposing to send aid “directly to people,” plus executive actions on drug pricing and pr...
Dr. Ania M. Jastreboff has authored peer‑reviewed reviews and clinical trial publications that situate GLP‑1 receptor agonists within modern obesity therapeutics and has led high‑profile clinical tria...
Pharmaceutical companies reacted to President Trump’s drug‑pricing campaign with a mix of public pushback, legal resistance to other federal price controls, and selectively cooperative deals that trad...
The Trump 2025 administration pursued a two-track healthcare strategy: on one hand, and . Analysts, administration fact sheets, and partisan critics describe overlapping actions: negotiated manufactur...
Oprah Winfrey’s name has been connected to several health and diet product promotions that later drew regulatory scrutiny: most prominently Eli Lilly and Novo Nordisk received FDA warning letters tied...
A guest who fainted during a White House event announcing changes to weight‑loss drug access was initially misidentified online as a Novo Nordisk executive named “Gordon Findlay/Finlay,” but multiple ...
A medical emergency did occur in the Oval Office on November 6, 2025, when a man standing near President Trump collapsed during a press event about lowering weight‑loss drug costs; the White House Med...
As of 2025, the scientifically proven and FDA‑approved treatments for diabetes include multiple medication classes (insulins, GLP‑1 receptor agonists, GIP/GLP‑1 dual agonists, SGLT2 inhibitors, metfor...
Trump-era actions through 2025 pivoted U.S. federal policy toward “most‑favored‑nation” (MFN) pricing, direct manufacturer deals and trade threats; by late 2025 the White House reported multiple MFN a...
The Trump administration issued multiple drug‑pricing directives in 2025 anchored by three executive orders and a campaign of MFN (most‑favored‑nation) negotiations and trade measures: an April 15, 20...
The FDA and state and private actors have recently escalated enforcement and oversight of compounded GLP‑1 and GIP/GLP‑1 products: federal warning letters numbering roughly 50–60 were posted in Septem...
Reports of deaths linked to weight‑loss drugs are documented in reputable reporting, but available sources show a mix of contexts — some deaths involve unlicensed or compounded copies, others are repo...